Guanghua School of Stomatology, Guangdong Provincial Key Laboratory of Stomatology, Stomatological Hospital, Sun Yat-Sen University, Guangzhou, 510055, People's Republic of China.
Sci Rep. 2020 Feb 14;10(1):2662. doi: 10.1038/s41598-020-59608-w.
In the last few years, V-domain Ig-containing suppressor of T cell activation(VISTA) has been reported as a prognostic biomarker in articles including various solid tumours. However, their conclusions have been controversial. For this reason, we performed this meta-analysis to further verify the prognostic value of VISTA in solid tumours. All relevant literature was identified from PubMed, Embase, the Cochrane Library and Web of Science. Ten studies, including 2, 440 patients, were eligible for the analysis. The pooled results showed that high expression of VISTA was associated with favourable overall survival (OS) than that seen with low expression of VISTA (7 studies, hazard ratio (HR) = 0.75, 95% confidence interval (CI): 0.66-0.86, P < 0.001). In addition, high expression of VISTA significantly correlated with high numbers of CD8 (+) tumour infiltrating lymphocytes (TILs) (3 studies, risk ratio (RR) = 1.80, 95% CI: 1.41-2.31, P < 0.001). In conclusion, these results indicate that VISTA is a potential prognostic biomarker in solid tumours.
在过去的几年中，V 结构域免疫球蛋白含有抑制 T 细胞活化因子（VISTA）已被报道为各种实体瘤的预后生物标志物。然而，他们的结论存在争议。基于此，我们进行了这项荟萃分析，以进一步验证 VISTA 在实体瘤中的预后价值。我们从 PubMed、Embase、Cochrane 图书馆和 Web of Science 中确定了所有相关文献。有 10 项研究，包括 2440 名患者，符合分析条件。汇总结果表明，与 VISTA 低表达相比，VISTA 高表达与更好的总生存期（OS）相关（7 项研究，风险比（HR）=0.75，95%置信区间（CI）：0.66-0.86，P<0.001）。此外，VISTA 高表达与 CD8（+）肿瘤浸润淋巴细胞（TILs）数量较多显著相关（3 项研究，风险比（RR）=1.80，95%CI：1.41-2.31，P<0.001）。总之，这些结果表明 VISTA 是实体瘤中一种有潜力的预后生物标志物。
